TY - JOUR
T1 - Multicenter epidemiological survey of pneumatosis intestinalis in Japan
AU - Intractable Diseases, the Health and Labour Sciences Research Group
AU - Ohmiya, Naoki
AU - Hirata, Ichiro
AU - Sakamoto, Hirotsugu
AU - Morishita, Toshifumi
AU - Saito, Eiko
AU - Matsuoka, Katsuyoshi
AU - Nagaya, Tadanobu
AU - Nagata, Shinji
AU - Mukae, Miyuki
AU - Sano, Koji
AU - Suzuki, Takayoshi
AU - Tarumi, Ken ichi
AU - Shimizu, Seiji
AU - Kawashima, Kousaku
AU - Hibi, Toshifumi
AU - Ohmiya, Naoki
AU - Tarumi, Ken ichi
AU - Imamura, Akimichi
AU - Minato, Yohei
AU - Matsueda, Kazuhiro
AU - Kuwata, Go
AU - Sakaguchi, Masahiro
AU - Saito, Daisuke
AU - Mikami, Sakae
AU - Fujishiro, Mitsuhiro
AU - Fujii, Shigehiko
AU - Umeno, Junji
AU - Aoi, Kenji
AU - Nutahara, Daisuke
AU - Kinjo, Fukunori
AU - Fujiya, Mikihiro
AU - Harada, Keita
AU - Matsushita, Mitsunobu
AU - Chiba, Toshimi
AU - Sasaki, Yutaka
AU - Tanaka, Shinji
AU - Aomi, Yoshiaki
AU - Kasugai, Kunio
AU - Yamamoto, Shojiro
AU - Yagi, Nobuaki
AU - Yoshie, Tomoo
AU - Yoshida, Masaki
AU - Fukudo, Shin
AU - Yamada, Takanori
AU - Kuriyama, Shigeru
AU - Miura, Soichiro
AU - Fujimoto, Yoshiya
AU - Niwa, Yasumasa
AU - Nishikawa, Takashi
AU - Okawa, Kiyotaka
N1 - Funding Information:
The authors thank Mrs. Hiromi Yamashita, Mrs. Norimi Shiraishi, and Mrs. Sumie Morishita for technical support. Intractable Diseases, the Health and Labour Sciences Research Group Naoki Ohmiya1, Ichiro Hirata1, Hirotsugu Sakamoto2, Toshifumi Morishita3, Eiko Saito4, Katsuyoshi Matsuoka5, Tadanobu Nagaya6, Shinji Nagata7, Miyuki Mukae8, Koji Sano9, Takayoshi Suzuki10, Ken-ichi Tarumi11, Seiji Shimizu12, Kousaku Kawashima13, Toshifumi Hibi14, Akimichi Imamura15, Yohei Minato16, Kazuhiro Matsueda17, Go Kuwata18, Masahiro Sakaguchi19, Daisuke Saito20, Sakae Mikami21, Mitsuhiro Fujishiro22, Shigehiko Fujii23, Junji Umeno24, Kenji Aoi25, Daisuke Nutahara26, Fukunori Kinjo27, Mikihiro Fujiya28, Keita Harada29, Mitsunobu Matsushita30, Toshimi Chiba31, Yutaka Sasaki32, Shinji Tanaka33, Yoshiaki Aomi34, Kunio Kasugai35, Shojiro Yamamoto36, Nobuaki Yagi37, Tomoo Yoshie38, Masaki Yoshida39, Shin Fukudo40, Takanori Yamada41, Kensuke Kitsugi41, Shigeru Kuriyama41, Soichiro Miura42, Yoshiya Fujimoto43, Yasumasa Niwa44, Takashi Nishikawa45, Kiyotaka Okawa46, Makoto Sanomura47, Masanao Nakamura48, Tsutomu Mizoshita49.1Departments of Gastroenterology and Advanced Endoscopy, Fujita Health University School of Medicine, 1-98 Kutsukake-cho, Toyoake, Aichi 470-1192, Japan;2Department of Medicine, Division of Gastroenterology, Jichi Medical University, Tochigi, Japan;3Division of Gastroenterology, Matsuyama Red Cross Hospital, Matsuyama, Japan;4Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan;5Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;6Department of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan;7Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan;8Department of Gastroenterology, Kitasato University, School of Medicine, Kanagawa, Japan;9Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan;10Department of Gastroenterology, Tokai University School of Medicine, Kanagawa, Japan;11Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan;12Departments of Gastroenterology and Hepatology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan;13Department of Gastroenterology, Shimane University School of Medicine, Izumo, Shimane, Japan;14Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan;15Division of Gastroenterology, Sapporo Kosei General Hospital, Sapporo;16Department of Gastroenterology, NTT Medical Center, Tokyo, Japan;17Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama, Japan;18Department of Gastroenterology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan;19Department of Gastroenterology, Moriguchi Keijinkai Hospital, Osaka, Japan;20Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan;21Department of Gastroenterology and Hepatology, Kobe City Medical Center West Hospital, Kobe, Hyogo, Japan;22Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;23Department of Gastroenterology and Hepatology, Kyoto Katsura Hospital, Kyoto, Japan;24Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;25Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan;26Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan;27Department of Endoscopy, University of the Ryukyus Hospital, Okinawa, Japan;28Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan;29Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;30Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan;31Division of Gastroenterology, Department of Internal Medicine Iwate Medical University, Morioka, Japan;32Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan;33Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan;34Department of Gastroenterology, Fukuoka University Chikushi Hospital, Fukuoka, Japan;35Department of Gastroenterology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan;36Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan;37Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;38Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;39Tohno Kousei Hospital, Mizunami, Gifu, Japan;40Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan;41First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan;42Department of Internal Medicine, National Defense Medical College, Saitama, Japan;43Gastroenterological Center, Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;44Department of, Endoscopy, Aichi Cancer Center Hospital, Aichi;45Nagahama City Hospital, Nagahama, Shiga;46Department of Gastroenterology, Osaka City Juso Hospital, Osaka, Japan;47Department of Gastroenterology, Hokusetsu General Hospital, Osaka, Japan;48Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan;49Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Pneumatosis intestinalis (PI) is a rare condition characterized by gas collection in the intestinal wall. We aimed to determine the etiology and affected segments associated with complications, treatment, and outcome. Methods: We conducted a multicenter epidemiological survey using a standardized data collection sheet in Japan. Complicating PI was defined as strangulation or bowel necrosis, bowel obstruction, adynamic ileus, sepsis, shock, and massive gastrointestinal bleeding requiring blood transfusion. Results: We enrolled 167 patients from 48 facilities. Multivariate analysis revealed that older age (adjusted OR, 1.05 and 95% confidence intervals [CI], 1.02–1.09, P = 0.0053) and chronic kidney disease (adjusted OR, 13.19 and 95% CI 1.04–167.62, P = 0.0468) were independent predictors of the small-bowel-involved type. Complicating PI was associated with the small-bowel-involved combined type (adjusted OR, 27.02 and 95% CI 4.80–152.01, P = 0.0002), the small-bowel-only type (adjusted OR, 3.94 and 95% CI 1.02–15.27, P = 0.0472), and symptomatic PI (adjusted OR, 16.24 and 95% CI 1.82–145.24, P = 0.0126). Oxygen therapy was performed in patients with a past history of bowel obstruction (adjusted OR, 13.77 and 95% CI 1.31–144.56, P = 0.0288) and surgery was performed in patients with complicating PI (adjusted OR, 8.93 and 95% CI 1.10–72.78, P = 0.0408). Antihypertensives (adjusted OR, 12.28 and 95% CI 1.07–140.79, P = 0.0439) and complicating PI (adjusted OR, 11.77 and 95% CI 1.053–131.526; P = 0.0453) were associated with exacerbation of PI. The complicating PI was the only indicator of death (adjusted OR, 14.40 and 95% CI 1.09–189.48, P = 0.0425). Discussion: Small-bowel-involved type and symptomatic PI were associated with complications which were indicators of poor prognosis.
AB - Background: Pneumatosis intestinalis (PI) is a rare condition characterized by gas collection in the intestinal wall. We aimed to determine the etiology and affected segments associated with complications, treatment, and outcome. Methods: We conducted a multicenter epidemiological survey using a standardized data collection sheet in Japan. Complicating PI was defined as strangulation or bowel necrosis, bowel obstruction, adynamic ileus, sepsis, shock, and massive gastrointestinal bleeding requiring blood transfusion. Results: We enrolled 167 patients from 48 facilities. Multivariate analysis revealed that older age (adjusted OR, 1.05 and 95% confidence intervals [CI], 1.02–1.09, P = 0.0053) and chronic kidney disease (adjusted OR, 13.19 and 95% CI 1.04–167.62, P = 0.0468) were independent predictors of the small-bowel-involved type. Complicating PI was associated with the small-bowel-involved combined type (adjusted OR, 27.02 and 95% CI 4.80–152.01, P = 0.0002), the small-bowel-only type (adjusted OR, 3.94 and 95% CI 1.02–15.27, P = 0.0472), and symptomatic PI (adjusted OR, 16.24 and 95% CI 1.82–145.24, P = 0.0126). Oxygen therapy was performed in patients with a past history of bowel obstruction (adjusted OR, 13.77 and 95% CI 1.31–144.56, P = 0.0288) and surgery was performed in patients with complicating PI (adjusted OR, 8.93 and 95% CI 1.10–72.78, P = 0.0408). Antihypertensives (adjusted OR, 12.28 and 95% CI 1.07–140.79, P = 0.0439) and complicating PI (adjusted OR, 11.77 and 95% CI 1.053–131.526; P = 0.0453) were associated with exacerbation of PI. The complicating PI was the only indicator of death (adjusted OR, 14.40 and 95% CI 1.09–189.48, P = 0.0425). Discussion: Small-bowel-involved type and symptomatic PI were associated with complications which were indicators of poor prognosis.
UR - http://www.scopus.com/inward/record.url?scp=85131170801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131170801&partnerID=8YFLogxK
U2 - 10.1186/s12876-022-02343-5
DO - 10.1186/s12876-022-02343-5
M3 - Article
C2 - 35641910
AN - SCOPUS:85131170801
SN - 1471-230X
VL - 22
JO - BMC Gastroenterology
JF - BMC Gastroenterology
IS - 1
M1 - 272
ER -